Serious adverse events-missing in action: comment on the article by Kremer et al
- PMID: 22674338
- DOI: 10.1002/art.34559
Serious adverse events-missing in action: comment on the article by Kremer et al
Comment on
-
A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone.Arthritis Rheum. 2012 Apr;64(4):970-81. doi: 10.1002/art.33419. Epub 2011 Oct 17. Arthritis Rheum. 2012. PMID: 22006202 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
